Rising US Sales, EU Milestone Boost SK Bio's Q1

Shift To Operating Profit

After strong first-quarter results, SK Biopharmaceuticals expects sales growth to accelerate as the US marketing environment improves and as EU sales of epilepsy drug cenobamate begin.

earnings growth
Sale Of Arvelle Stake Also Reflected In Q1 • Source: Alamy

SK Biopharmaceuticals Co., Ltd has reported a sharp rise in first-quarter sales and shifted to an operating profit on the back of rising prescriptions of Xcopri (cenobamate) in the US and the receipt of a milestone payment for the marketing authorization of the epilepsy drug in Europe.

On a consolidated basis, the company’s Q1 sales jumped to KRW140bn ($123.8m) from KRW16.1bn in the previous quarter. It also...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Neurological

More from Therapy Areas

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By 

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

BioNTech/BMS Bispecific Shows Early Promise In Small Cell Lung Cancer

 

An updated abstract from the World Conference on Lung Cancer has given analysts confidence in BioNTech’s VEGF-A/PD-L1 bispecific challenger

China-Originated Assets Lead Global GLP-1 Deals

 
• By 

The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.